We have recently reported a series of Lys-covalent agents targeting the BIR3 domain of the X-linked inhibitor of apoptosis protein (XIAP) using a benzamide-sulfonyl fluoride warhead. Using XIAP as a model system, we further investigated a variety of additional warheads that can be easily incorporated into binding peptides and analyzed their ability to form covalent adducts with lysine and other amino acids, including tyrosine, histidine, serine, and threonine, using biochemical and biophysical assays. Moreover, we tested aqueous, plasma stability, cell permeability, and cellular efficacy of the most effective agents. These studies identified aryl-fluoro sulfates as likely the most suitable electrophiles to effectively form covalent adducts with Lys, Tyr, and His residues, given that these agents were cell permeable and stable in aqueous buffer and in plasma. Our studies contain a number of general findings that open new possible avenues for the design of potent covalent protein−protein interaction antagonists.
We have recently investigated the
reactivity of aryl-fluorosulfates
as warheads to form covalent adducts with Lys, Tyr, and His residues.
However, the rate of reaction of aryl-fluorosulfates seemed relatively
slow, putting into question their effectiveness to form covalent adducts
in cell. Unlike the previously reported agents that targeted a relatively
remote Lys residue with respect to the target’s binding site,
the current agents were designed to more directly juxtapose an aryl-fluorosulfate
with a Lys residue that is located within the binding pocket of the
BIR3 domain of X-linked inhibitor of apoptosis protein (XIAP). We
found that such new agents can effectively and rapidly form a covalent
adduct with XIAP-BIR3 in vitro and in cell, approaching the rate of
reaction, cellular permeability, and stability that are similar to
what attained by acrylamides when targeting Cys residues. Our studies
further validate aryl-fluorosulfates as valuable Lys-targeting electrophiles,
for the design of inhibitors of both enzymes and protein–protein
interactions.
Recently, it was reported that tetrapeptides cyclized via lactam bond between the amino terminus and a glutamic residue in position 4 (termed here N‐lock) can nucleate helix formation in longer peptides. We applied such strategy to derive N‐locked covalent BH3 peptides that were designed to selectively target the anti‐apoptotic protein Bfl‐1. The resulting agents were soluble in aqueous buffer and displayed a remarkable (low nanomolar) affinity for Bfl‐1 and cellular activity. The crystal structure of the complex between such N‐locked covalent peptide and Bfl‐1 provided insights on the geometry of the N‐locking strategy and of the covalent bond between the agent and Bfl‐1.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.